The first malaria vaccine for approved babies for use

The first malaria treatment suitable for babies and very young children were approved for use.

African countries are expected to be spread in several weeks.

So far, there have been no malaria drugs specifically for babies.

Instead, it was treated with versions made for elderly children who present the risk of extreme doses.

In 2023 – the year where the latest figures were available – Malaria was related to about 597,000 deaths.

Almost all of the deaths were in Africa, three-quarters were children under five years old.

There was no malaria treatment for children, but so far there was nothing special for small babies and small children with less than 4.5 kg or 10lb.

Instead, treated with drugs made for older children.

However, these are doses for these older children, liver functions may not be safe for babies that are still developing and developing their bodies differently.

Experts say that this is caused by what is described as the “cure.”

Now a new medicine developed by the Novartis drug company, is approved by the Swiss power and probably in areas and countries with the highest rates of malaria for several weeks.

Novartis plans to present him in a very profitable way.

The company’s CEO Vas Narasimhan said that this is an important point.

“For more than three decades, we were ruthlessly used to ensure the scientific progress they need in the fight against Malaria.

“With our partners, we are proud to move forward to develop the first clinically proven malaria treatment for newborns and young babies, even the smallest and most sensitive ones can finally be worthy.”

In some countries, Coartem Baby or Riammet Baby, Novartis was developed by the British, Switzerland, Switzerland and Dutch governments, as well as the World Bank and Rockefeller Foundation.

Eight African people also participated in the assessment and testing of the drug and are expected to be within the first place.

MMV Director General Martin Fitchet said that this is another important step on the road to end the huge number of endings by Malaria.

“Malaria is one of the most deadly diseases of the world among children. However, proper resources and carefully, can be eliminated.

“Coartem Baby’s approval provides a necessary medication with an optimized dose to treat another indifferent group and offers a valuable addition to the Antimarial toolbox.”

Dr. Marvelle Brown, Hertfordshire’nin Health, Medical and Lifestyle School University, Associate Professor, said that babies and young children should be seen as a great progress.

“The death rate for malarian infections in Saharan Africa is extremely high – more than 76% of deaths in children under the age of 5 occur.

“The increase in death from malaria is more complex in infants with sickle cell disease, primarily in connection with a weak immune system.

“In terms of a public health, Novartıs can help reduce the unequacy in obtaining this profit to make this profit.”